Takeda se queda con... Shire

.

Takeda reached an agreement to acquire Shire for approximately 46 billion pounds ($62.4 billion), with the transaction including $30.33 per share in cash and 0.839 shares of the Japanese drugmaker, the companies announced Tuesday. The deal has been approved by both boards, and is expected to close in the first half of 2019.

Christophe Weber, Takeda CEO, said "Shire's highly complementary product portfolio and pipeline, as well as experienced employees, will accelerate our transformation for a stronger Takeda." Weber added "together, we will be a leader in providing targeted treatments in gastroenterology, neuroscience, oncology, rare diseases and plasma-derived therapies."

According to the companies, upon the closing of the transaction, Takeda shareholders will own approximately 50 percent of the combined group. The Japanese drugmaker indicated that the purchase will allow for "significant recurring cost synergies," with savings of about $600 million in duplicated R&D costs and overall savings of $1.4 billion by the third year.

"The cost synergies seem to be much bigger than expected in the next three years," remarked Credit Suisse analyst Fumiyoshi Sakai.

Ver 

Ver también:
La japonesa Takeda Pharma compra por 52.200 millones la biotecnológica inglesa Shire